US20020183326A1 - 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them - Google Patents
1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- US20020183326A1 US20020183326A1 US10/038,777 US3877702A US2002183326A1 US 20020183326 A1 US20020183326 A1 US 20020183326A1 US 3877702 A US3877702 A US 3877702A US 2002183326 A1 US2002183326 A1 US 2002183326A1
- Authority
- US
- United States
- Prior art keywords
- group
- alkyl
- compound according
- groups
- aromatic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=NN=C2C3=C(N=CC=C3)C([2*])=NN12.[3*]C Chemical compound [1*]C1=NN=C2C3=C(N=CC=C3)C([2*])=NN12.[3*]C 0.000 description 13
- CPJPUSXMSXPYRR-UHFFFAOYSA-N COC1=C(OC2CCCC2)C=C(C)C=C1 Chemical compound COC1=C(OC2CCCC2)C=C(C)C=C1 CPJPUSXMSXPYRR-UHFFFAOYSA-N 0.000 description 5
- GHPODDMCSOYWNE-UHFFFAOYSA-N CC1=CC=C2OCOC2=C1 Chemical compound CC1=CC=C2OCOC2=C1 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- This invention relates to new therapeutically useful heterocyclic compounds, to process for their preparation and to pharmaceutical compositions containing them.
- PDE 4 phosphodiesterase 4
- EP-A-85,840 discloses a series of triazolo-phthalazine derivatives of formula:
- the present invention provides a compound which is a heterocycle of formula (I):
- R 1 represents a hydrogen atom or a —(CH 2 ) m —Y group, wherein m is an integer from 0 to 4 and Y represents an alkyl, haloalkyl (preferably trifluoromethyl), alkoxy, alkoxycarbonyl, C 3 -C 7 cycloalkyl, norbornyl (preferably 2-norbornyl) or phenylalkenyl group, or an aromatic group (preferably phenyl or pyridyl) which aromatic group Y may optionally be substituted by one or more halogen atoms;
- R 2 represents an aromatic group (preferably phenyl, naphthyl or thienyl) which aromatic group may optionally be substituted by one or more halogen atoms or alkyl, alkoxy, C 3 -C 6 cycloalkoxy, methylenedioxy, nitro, dialkylamino or trifluoromethyl groups; and
- R 3 represents a hydrogen or halogen atom (preferably chloro) or an alkyl group
- alkyl, haloalkyl, alkenyl or alkynyl groups and moieties such as in the alkoxy groups, mentioned in relation to the groups R 1 —R 3 in compounds of the invention are usually “lower” alkyl, that is containing up to 6 and particularly up to 4 carbon atoms, the hydrocarbon chain being branched or straight.
- alkyl groups and moieties are CH 3 , C 2 H 5 , C 3 H 7 , i-C 3 H 7 , n—C 4 H 9 , i—C 4 H 9 , isoamyl and neopentyl.
- R 1 are the preferred alkyl groups mentioned above, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl and cyclopenthylmethyl.
- R 2 examples are phenyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 4-fluorophenyl and 3-nitrophenyl.
- R 3 are hydrogen, alkyl or chloro, preferably in the 8- or 9-positions.
- heterocyclic compounds of formula (I) can be prepared from the corresponding hydrazine derivative of formula (II):
- R 2 and R 3 are as defined above, by reaction with a reactive derivative of a carboxylic acid of the general formula (III):
- R 1 is as defined above.
- the reactive derivative of the said carboxylic acid may be, for example, a halide (preferably chloride), an anhydride or a mixed anhydride.
- the reaction is preferably carried out in an inert organic solvent such as methylene chloride, dioxane or tetrahydrofuran, in the presence of an organic nitrogen-containing base, e.g. triethylamine and at a temperature between ⁇ 10° C. and +60° C.
- an organic nitrogen-containing base e.g. triethylamine
- the hydrazine derivative of formula (II) may be prepared by:
- R 2 and R 3 are as defined above and R 4 is an alkyl group, with a phosphorus halide or phosphorus oxyhalide (preferably phosphorus oxychloride), to form the intermediate compound of formula (VI):
- R 2 and R 3 are as defined above and X is a chlorine or bromine atom;
- R 5 is an alkyl group
- R 2 , R 3 and R 5 are as defined above;
- reaction of (VI) with the alkyl carbazate of formula (VII) to obtain the corresponding alkoxycarbonylhydrazine derivative (VIII), is preferably carried out in the presence of an organic solvent as tetrahydrofuran or dioxan at a temperature of from 60° C. to the boiling point of the reaction medium.
- the alkoxycarbonylhydrazine derivative (VIII) may, for example, be transformed into the hydrazine derivative (II) at room temperature in hydrogen chloride-ethanol saturated solution.
- hydrazone derivatives of formula (V) are known compounds which can be prepared from the corresponding 2-acylnicotinic acid by known methods described in the literature.
- Compound A is 3-isobutyl-6-phenyl-1,2,4-triazolo[3,4-a]phthalazine, a compound included in EP-A-8-5,840.
- the compounds of formula (I) are cyclic phosphodiestrerase inhibitors, in particular type 4 cyclic AMP phosphodiesterase inhibitors.
- the compounds are also capable of blocking the production of some pro-inflammatory cytokines such as, for example, TNF ⁇ .
- pro-inflammatory cytokines such as, for example, TNF ⁇ .
- they can be used in the treatment of allergic, inflammatory and immunological diseases, as well as those disease or conditions where the blockade of pro-inflammatory cytokines or the selective inhibition of PDE 4 could be of benefit.
- These diseases states include asthma, rheumatoid arthritis, osteoarthritis, osteoporosis, bone-formation disorders, glomerulonephritis, multiple sclerosis, Graves ophtalmopathy, myasthenia gravis, insulin-dependent diabetes mellitus, graft rejection, gastrointestinal disorders such as ulcerative colitis or Crohn disease, septic shock, adult distress respiratory syndrome, and skin diseases such as atopic dermatitis, contact dermatitis, acute dermatomyositis and psoriasis.
- the compounds of the present invention are also of benefit when administered in combination with other drugs such as steroids and immunosuppressive agents, such as cyclosporin A, rapamycin or T-cell receptor blockers.
- other drugs such as steroids and immunosuppressive agents, such as cyclosporin A, rapamycin or T-cell receptor blockers.
- the administration of the compounds allows a reduction of the dosage of the other drugs, thus preventing the appearance of the undesired side effects associated with both steroids and immunosuppressants.
- the compounds of the invention have also shown their efficacy in blocking, after preventive and/or curative treatment, the erosive and ulcerogenic effects induced by a variety of etiological agents, such as antiinflammatory drugs (steroidal or non-steroidal antiinflammatory agents), stress, ammonia, ethanol and concentrated acids. They can be used alone or in combination with antacids and/or antisecretory drugs in the preventive and/or curative treatment of gastrointestinal pathologies like drug-induced ulcers, peptic ulcers, H. Pylori -related ulcers, esophagitis and gastro-esophageal reflux disease.
- antiinflammatory drugs steroidal or non-steroidal antiinflammatory agents
- stress erosive and ulcerogenic effects induced by a variety of etiological agents
- antacids and/or antisecretory drugs in the preventive and/or curative treatment of gastrointestinal pathologies like drug-induced ulcers, peptic ulcers, H. Pylori -related ulcers, es
- the present invention also provides a heterocyclic compound of formula (I) for use in a method of treatment of the human or animal body by therapy, particularly for use as a PDE 4 inhibitor or to block the production of a pro-inflammatory cytokine such as TNF ⁇ .
- the present invention additionally provides a pharmaceutical composition which comprises, as active ingredient, at least one heterocyclic compound of formula (I), and a pharmaceutically acceptable carrier or diluent.
- compositions are in a form suitable for oral, inhalation, rectal, transdermal, nasal, topical or parenteral administration.
- compositions of this invention are well known per se and the actual excipients used depend inter alia on the intended method of administration of the compositions.
- compositions of this invention are preferably adapted for administration per os.
- the compositions for oral administration may take the form of tablets, capsules, lozenges or effervescent granules or liquid preparations such as elixirs, syrups or suspensions, all containing one or more compounds of the invention.
- Such preparations may be made by methods well known in the art, for instance by mixing the heterocyclic compound of formula (I) with the pharmaceutically acceptable carrier or diluent.
- the diluents which may be used in the preparation of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents if desided.
- Tablets or capsules may conveniently contain from 1 to 100 mg and preferably from 5 to 50 mg of active ingredient.
- the compounds may also be incorporated into pellets coated with appropriate natural or synthetic polymers known in the art to produce sustained release characteristics or incorporated with polymers into tablet form to produce the same characteristics.
- the liquid compositions adapted for oral use may be in the form of solutions, suspensions or aerosols.
- the solutions may be aqueous or aqueous-alcoholic solutions in association with, for example, sucrose or sorbitol to form a syrup.
- the suspensions may comprise an insoluble or microencapsulated form of an active compound of the invention in association with water and other acceptable solvents together with a suspending agent or flavouring agent.
- compositions for inhalation administration may be in the form of solutions, suspensions or micronized powder, contained in an appropriate inhaler.
- compositions for parenteral injection may be prepared, which may or may not be freeze-dried and which may be dissolved in water or an appropriate parenteral injection fluid.
- the doses of the heterocyclic compound depend on the desired effect and duration of the treatment; adult doses are generally from 1 mg to 100 mg per day. In general the physician will decide the posology, taking into account the age and weight of the patient being treated.
- microcrystalline suspension prepared with these ingredients was introduced in the inhalation-flasks at a volume of 20 ml per flask with a filling machine.
- the flasks were furnished with an appropriate valve which released 0.2 ml of suspension for each activation (0.4 mg of active compound).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
wherein R1 represents a hydrogen atom or a —(CH2)M—Y group, wherein m is an integer from 0 to 4 and Y represents an alkyl, haloalkyl, alkoxy, alkoxycarbonyl, C3-C7 cycloalkyl, norbornyl or phenylalkenyl group, or an aromatic group which aromatic group ^ may optionally be substituted by one or more halogen atoms; R2 represents an aromatic group which aromatic group may optionally be substituted by one or more halogen atoms or alkyl, alkoxy, C3-C6 cycloalkoxy, methylenedioxy, nitro, dialkylamino or trifluoromethyl groups, and R3 represents a hydrogen or halogen atom or an alkyl group, and pharmaceutically acceptable salts thereof, processes for preparing the same. The compounds are phosphodiesterase 4 inhibitors.
Description
- This invention relates to new therapeutically useful heterocyclic compounds, to process for their preparation and to pharmaceutical compositions containing them.
- It is known that inhibitors of phosphodiesterase 4 (PDE 4) are useful in the treatment of inflammatory and allergic processes such as asthma, non-steroidal antiinflammatory drugs-induced gastrointestinal damage and atopic dermatitis.
-
- which are useful as anxiolytic agents.
- We have now found that the presence of a pyridine ring instead of the benzo ring in the above structure, provides new compounds which inhibit cyclic phosphodiesterases, in particular type 4 cyclic phosphodiesterases and have a very low emetic activity (10-100 times less active than rolipram in inducing emesis in dogs).
-
- wherein:
- R1 represents a hydrogen atom or a —(CH2)m—Y group, wherein m is an integer from 0 to 4 and Y represents an alkyl, haloalkyl (preferably trifluoromethyl), alkoxy, alkoxycarbonyl, C3-C7 cycloalkyl, norbornyl (preferably 2-norbornyl) or phenylalkenyl group, or an aromatic group (preferably phenyl or pyridyl) which aromatic group Y may optionally be substituted by one or more halogen atoms;
- R2 represents an aromatic group (preferably phenyl, naphthyl or thienyl) which aromatic group may optionally be substituted by one or more halogen atoms or alkyl, alkoxy, C3-C6 cycloalkoxy, methylenedioxy, nitro, dialkylamino or trifluoromethyl groups; and
- R3 represents a hydrogen or halogen atom (preferably chloro) or an alkyl group,
- and pharmaceutically acceptable salts thereof.
- The alkyl, haloalkyl, alkenyl or alkynyl groups and moieties, such as in the alkoxy groups, mentioned in relation to the groups R1—R3 in compounds of the invention are usually “lower” alkyl, that is containing up to 6 and particularly up to 4 carbon atoms, the hydrocarbon chain being branched or straight. Examples of alkyl groups and moieties are CH3, C2H5, C3H7, i-C3H7, n—C4H9, i—C4H9, isoamyl and neopentyl.
- When any of the groups, such as R1 or R2 has a chiral centre, the compounds of formula (I) exhibit optical isomerism and the isomers are within the scope of the present invention.
- Examples of R1 are the preferred alkyl groups mentioned above, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl and cyclopenthylmethyl.
- Examples of R2 are phenyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 4-fluorophenyl and 3-nitrophenyl.
- Examples of R3 are hydrogen, alkyl or chloro, preferably in the 8- or 9-positions.
- The most preferred compounds of the invention are
- 6-(4-fluorophenyl)-3-isobutyl-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine, 3-cyclopropylmethyl-6-(3-nitrophenyl)-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine, 3-cyclopropyl-6-phenyl-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine, and 3-cyclobutylmethyl-6-(3-nitrophenyl)-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine.
-
- wherein
- R2 and R3 are as defined above, by reaction with a reactive derivative of a carboxylic acid of the general formula (III):
- HOOC—R1 (III)
- wherein R1 is as defined above. The reactive derivative of the said carboxylic acid may be, for example, a halide (preferably chloride), an anhydride or a mixed anhydride.
- The reaction is preferably carried out in an inert organic solvent such as methylene chloride, dioxane or tetrahydrofuran, in the presence of an organic nitrogen-containing base, e.g. triethylamine and at a temperature between −10° C. and +60° C. In the reaction, the corresponding hydrazide of general formula (IV) is first formed:
- wherein R1, R2 and R3 are as defined above. A suspension of this hydrazide (IV) in an organic solvent such as dioxane, tetrahydrofuran, isopropanol or n-butanol, is heated, for example at the boiling point of the solvent, to give the corresponding heterocyclic compound of formula (I).
- The hydrazine derivative of formula (II) may be prepared by:
-
-
- wherein R2 and R3 are as defined above and X is a chlorine or bromine atom;
- 2) reacting compound (VI) with an alkyl carbazate (preferably t-butyl carbazate) of formula (VII):
- H2N—NH—COOR5 (VII)
-
- wherein R2, R3 and R5 are as defined above; and
- 3) treating compound (VIII) with hydrogen chloride in an anhydrous solvent as ethanol.
- The reaction between the hydrazone of formula (V) and a phosphorus halide or phosphorus oxyhalide is carried out with an excess of reagent at a temperature from 80° C. to 120° C., then removed the excess of reagent and poured into cold water. In this way the compound (VI) is obtained.
- The reaction of (VI) with the alkyl carbazate of formula (VII) to obtain the corresponding alkoxycarbonylhydrazine derivative (VIII), is preferably carried out in the presence of an organic solvent as tetrahydrofuran or dioxan at a temperature of from 60° C. to the boiling point of the reaction medium.
- The alkoxycarbonylhydrazine derivative (VIII) may, for example, be transformed into the hydrazine derivative (II) at room temperature in hydrogen chloride-ethanol saturated solution.
- The hydrazone derivatives of formula (V) are known compounds which can be prepared from the corresponding 2-acylnicotinic acid by known methods described in the literature.
- The inhibition of cyclic nucleotide phosphodiesterase 4 from guinea-pig hearts was performed using 96-well microtiter plates as described by Verghese et al., (Molecular Pharmacology, 47, 1164-1171 (1995)).
- The results from such test are shown in Table 1.
TABLE 1 PDE4 Compound * IC50 (μM) A 10 6 2 7 0.3 12 3 31 0.2 47 0.7 55 0.2 60 0.1 61 2 109 0.04 112 0.7 113 0.2 - Compound A is 3-isobutyl-6-phenyl-1,2,4-triazolo[3,4-a]phthalazine, a compound included in EP-A-8-5,840.
- As it can be seen from Table 1, the compounds of formula (I) are cyclic phosphodiestrerase inhibitors, in particular type 4 cyclic AMP phosphodiesterase inhibitors. The compounds are also capable of blocking the production of some pro-inflammatory cytokines such as, for example, TNFα. Thus, they can be used in the treatment of allergic, inflammatory and immunological diseases, as well as those disease or conditions where the blockade of pro-inflammatory cytokines or the selective inhibition of PDE 4 could be of benefit.
- These diseases states include asthma, rheumatoid arthritis, osteoarthritis, osteoporosis, bone-formation disorders, glomerulonephritis, multiple sclerosis, Graves ophtalmopathy, myasthenia gravis, insulin-dependent diabetes mellitus, graft rejection, gastrointestinal disorders such as ulcerative colitis or Crohn disease, septic shock, adult distress respiratory syndrome, and skin diseases such as atopic dermatitis, contact dermatitis, acute dermatomyositis and psoriasis.
- They can also be used as improvers of cerebrovascular function as well as in the treatment of other CNS related diseases such as dementia, Alzheimer's disease, depression, and as nootropic agents.
- The compounds of the present invention are also of benefit when administered in combination with other drugs such as steroids and immunosuppressive agents, such as cyclosporin A, rapamycin or T-cell receptor blockers. In this case the administration of the compounds allows a reduction of the dosage of the other drugs, thus preventing the appearance of the undesired side effects associated with both steroids and immunosuppressants.
- The compounds of the invention have also shown their efficacy in blocking, after preventive and/or curative treatment, the erosive and ulcerogenic effects induced by a variety of etiological agents, such as antiinflammatory drugs (steroidal or non-steroidal antiinflammatory agents), stress, ammonia, ethanol and concentrated acids. They can be used alone or in combination with antacids and/or antisecretory drugs in the preventive and/or curative treatment of gastrointestinal pathologies like drug-induced ulcers, peptic ulcers,H. Pylori-related ulcers, esophagitis and gastro-esophageal reflux disease.
- They can also be used in the treatment of pathological situations where damage to the cells or tissues is produced through conditions like anoxia or the production of an excess of free radicals. Examples of such beneficial effects are the protection of cardiac tissue after coronary artery occlusion or the prolongation of cell and tissue viability when the compounds of the invention are added to preserving solutions intended for storage of transplant organs or fluids such as blood or sperm. They are also of benefit on tissue repair and wound healing.
- The present invention also provides a heterocyclic compound of formula (I) for use in a method of treatment of the human or animal body by therapy, particularly for use as a PDE 4 inhibitor or to block the production of a pro-inflammatory cytokine such as TNFα.
- The present invention additionally provides a pharmaceutical composition which comprises, as active ingredient, at least one heterocyclic compound of formula (I), and a pharmaceutically acceptable carrier or diluent.
- Preferably the compositions are in a form suitable for oral, inhalation, rectal, transdermal, nasal, topical or parenteral administration.
- The pharmaceutically-acceptable carriers or diluents which are admixed with the active compound or compounds to form the compositions of this invention are well known per se and the actual excipients used depend inter alia on the intended method of administration of the compositions.
- Compositions of this invention are preferably adapted for administration per os. The compositions for oral administration may take the form of tablets, capsules, lozenges or effervescent granules or liquid preparations such as elixirs, syrups or suspensions, all containing one or more compounds of the invention. Such preparations may be made by methods well known in the art, for instance by mixing the heterocyclic compound of formula (I) with the pharmaceutically acceptable carrier or diluent.
- The diluents which may be used in the preparation of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents if desided. Tablets or capsules may conveniently contain from 1 to 100 mg and preferably from 5 to 50 mg of active ingredient. The compounds may also be incorporated into pellets coated with appropriate natural or synthetic polymers known in the art to produce sustained release characteristics or incorporated with polymers into tablet form to produce the same characteristics.
- The liquid compositions adapted for oral use may be in the form of solutions, suspensions or aerosols. The solutions may be aqueous or aqueous-alcoholic solutions in association with, for example, sucrose or sorbitol to form a syrup. The suspensions may comprise an insoluble or microencapsulated form of an active compound of the invention in association with water and other acceptable solvents together with a suspending agent or flavouring agent.
- Compositions for inhalation administration may be in the form of solutions, suspensions or micronized powder, contained in an appropriate inhaler.
- Compositions for parenteral injection may be prepared, which may or may not be freeze-dried and which may be dissolved in water or an appropriate parenteral injection fluid.
- In human therapy, the doses of the heterocyclic compound depend on the desired effect and duration of the treatment; adult doses are generally from 1 mg to 100 mg per day. In general the physician will decide the posology, taking into account the age and weight of the patient being treated.
- The following Examples further illustrate the invention.
- a) A mixture of t-butoxycarbonylhydrazone of 2-benzoylnicotinic acid (45 g; 13.2 mols) in phosphorus oxychloride (500 ml) was boiled under reflux for one hour, then the excess of phosphorus oxychloride was removed under reduced pressure, the residue treated with ice-water and extracted twice with methylene chloride. The organic solution was washed with 4% sodium bicarbonate aqueous solution, with brine and after drying (Na2SO4), the solvent removed in vacuo. The obtained solid was collected with a mixture of diethyl ether-petrol ether 1:1 to give 5-chloro-8-phenylpyrido[2,3-d]pyridazine as a red solid, (25.4 g; 80% yield).
- b) To a suspension of the above compound (18.2; 0.075 mols) in anhydrous tetrahydrofuran (180 ml), t-butyl carbazate (10.0 g; 0.075 mols) was added and the mixture was boiled under reflux for one hour. After cooling the crystallized solid was collected by filtration when 5-t-butoxycarbonylhydrazino-8-phenylpyrido[2,3-d]pyridazine was obtained (28.5 g). This compound was solved in ethanol (150 ml), hydrogen chloride in ethanol saturated solution (100 ml) was added and the resulting mixture stirred at room temperature for 15 hours. A solid was formed which was collected by filtration and washed with diethyl ether to give 5-hydrazino-8-phenylpyrido[2,3-d]pyridazine dihydrochloride (21.6 g; 92% yield).
- c) To a suspension of 5-hydrazino-8-phenylpyrido[2,3-d]pyridazine dihydrochloride (1.24 g; 0.004 mols) in methylene chloride (30 ml), triethylamine (1.9 ml; 0.013 mols) was added, then stirred at room temperature for 15 minutes and pivaloyl chloride (0.5 ml; 0.0044 moles) slowly added. After stirring at room temperature for two hours, water (30 ml) was added, the formed yellow solid, collected by filtration and washed with diethyl ether to give the intermediate hydrazide. This compound was suspended in n-butanol (30 ml), boiled under reflux for 15 hours and on cooling, crystallized a white solid which was collected by filtration and washed with diethyl ether. The obtained solid was purified by flash column chromatography with silica gel and methylene chloride-ethanol-ammonium hydroxide 200:8:1 as eluent. 3-t-butyl-6-phenyl-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine was obtained (0.83 g; 69% yield), m.p. 188.1 (determined by Differential Scanning Calorimetry, Perkin-Elmer DSC-7 (compound 8 in Table 2).
- The heterocyclic compounds of formula (I) in Table 2 were prepared according to the processes disclosed in this Example, but with the appropriate starting materials.
TABLE 2 Compound R1 R2 R3 m.p. ° C. 1 H C6H5 H 215.8 2 CH3 ″ ″ 215.9 3 C2H5 ″ ″ 194.1 4 C3H7 ″ ″ 168.1 5 i-C3H7 ″ ″ 176.8 6 n-C4H9 ″ ″ 162.9 7 i-C4H9 ″ ″ 179.7 8 t-C4H9 ″ ″ 188.1 9 n-C5H11 ″ ″ 137.4 10 neopentyl ″ ″ 216.3 11 t-amyl ″ ″ 153 12 cyclopropyl ″ ″ 244.3 13 cyclobutyl ″ ″ 218 14 cyclopentyl ″ ″ 202.4 15 cyclohexyl ″ ″ 196.3 16 cyclopropyl-CH2 ″ ″ 195 17 cyclobutyl-CH2 ″ ″ 183 18 cyclopentyl-CH2 ″ ″ 193 19 cyclohexyl-CH2 ″ ″ 212.8 20 2-norbornyl-CH2 ″ ″ 217 21 C6H5 ″ ″ 304.1 22 C6H5—CH2 ″ ″ 192 23 C6H5—CH2CH2 ″ ″ 176 24 C6H5—CH═CH ″ ″ 278 25 CF3 ″ ″ 192.5 26 H3CO—CH2 ″ ″ 159 27 2-ClC6H4 ″ ″ 206 28 4-pyridyl ″ ″ 333.4 29 CH3 4-FC6H4 ″ 276 30 n-C4H9 ″ ″ 111 31 i-C4H9 ″ ″ 135 32 t-C4H9 ″ ″ 195 33 neopentyl ″ ″ 216 34 cyclopropyl ″ ″ 245 35 cyclohexyl ″ ″ 177 36 cyclopropyl-CH2 ″ ″ 160 37 cyclobutyl-CH2 ″ ″ 132 38 cyclopentyl-CH2 ″ ″ 162 39 2-norbornyl-CH2 ″ ″ 161 40 C6H5—CH═CH ″ ″ 272 41 C2H5OOC—CH2 ″ ″ 42 i-C4H9 3-FC6H4 ″ 147 43 neopentyl ″ ″ 190 44 cyclopropyl ″ ″ 222 45 cyclopropyl-CH2 ″ ″ 174 46 cyclobutyl-CH2 ″ ″ 139 47 cyclopentyl-CH2 ″ ″ 145 48 i-C4H9 2-FC6H4 ″ 202 49 t-C4H9 ″ ″ 212 50 neopentyl ″ ″ 235 51 cyclopropyl ″ ″ 262 52 cyclopropyl-CH2 ″ ″ 224 53 i-C4H9 4-ClC6H4 ″ 133 54 cyclopropyl ″ ″ 208 55 i-C4H9 3-ClC6H4 ″ 113 56 t-C4H9 ″ ″ 160 57 neopentyl ″ ″ 177 58 t-amyl ″ ″ 150 59 cyclopropyl ″ ″ 189 60 cyclopropyl-CH2 ″ ″ 136 61 cyclobutyl-CH2 ″ ″ 156 62 cyclopentyl-CH2 ″ ″ 147 63 i-C4H9 2-ClC6H4 ″ 182 64 neopentyl ″ ″ 216 65 cyclopropyl ″ ″ 198 66 i-C4H9 4-BrC6H4 ″ 135 67 neopentyl ″ ″ 204 68 cyclopropyl ″ ″ 208 69 cyclopropyl-CH2 ″ ″ 140 70 cyclopentyl-CH2 ″ ″ 187 71 2-norbornyl-CH2 ″ ″ 174 72 i-C4H9 3-BrC6H4 ″ 152 73 t-C4H9 ″ ″ 160 74 neopentyl ″ ″ 177 75 cyclopropyl ″ ″ 186 76 cyclopentyl-CH2 ″ ″ 143 77 i-C4H9 3,4-diClC6H3 ″ 143 78 neopentyl ″ ″ 215 79 i-C4H9 3-CH3C6H4 ″ 119 80 cyclopropyl ″ ″ 206 81 i-C4H9 2-CH3C6H4 ″ 147 82 neopentyl ″ ″ 191 83 cyclopropyl ″ ″ 200 84 i-C4H9 3,4-diCH3C6H3 ″ 165 85 neopentyl ″ ″ 184 86 cyclopropyl ″ ″ 182 87 cyclohexyl ″ ″ 211 88 cyclopentyl-CH2 ″ ″ 144 89 i-C4H9 3-CF3C6H4 ″ 139 90 cyclopropyl ″ ″ 172 91 cyclopentyl-CH2 ″ ″ 141 92 i-C4H9 4-CH3OC6H4 ″ 177 93 cyclopropyl ″ ″ 164 94 i-C4H9 3-CH3OC6H4 ″ 119 95 neopentyl ″ ″ 155 96 cyclopropyl ″ ″ 192 97 i-C4H9 2-CH3OC6H4 ″ 181 98 cyclopropyl ″ ″ 211 99 ″ 3,4-diCH3OC6H3 ″ 177 100 i-C4H9 ″ 158 101 t-C4H9 ″ 251 102 neopentyl ″ 208 103 cyclopropyl ″ 208 104 i-C4H9 ″ 193 105 t-C4H9 ″ 210 106 neopentyl ″ 219 107 cyclopropyl ″ 162 108 i-C3H7 3-NO2C6H4 ″ 176 109 i-C4H9 ″ ″ 178 110 neopentyl ″ ″ 229 111 cyclopropyl ″ ″ 234 112 cyclopropyl-CH2 ″ ″ 164 113 cyclobutyl-CH2 ″ ″ 150 114 cyclopentyl-CH2 ″ ″ 183 115 cyclopropyl 3-(CH3)2NC6H4 ″ 213 116 i-C4H9 2-naphthyl ″ 140 117 cyclopropyl ″ ″ 212 118 i-C4H9 2-thienyl ″ 196 119 cyclopropyl ″ ″ 214 120 i-C4H9 3-thienyl ″ 166 121 cyclopropyl ″ ″ 183 122 i-C4H9 C6H5 8-H3C 170 123 neopentyl ″ ″ 221 124 cyclopropyl ″ ″ 185 125 cyclopentyl-CH2 ″ ″ 163 126 2-norbornyl-CH2 ″ ″ 193 127 i-C4H9 ″ 9-Cl 174 128 cyclopropyl ″ ″ 149 129 cyclopropyl-CH2 ″ ″ 175 130 cyclopentyl-CH2 ″ ″ 175 - The following Examples illustrate pharmaceutical compositions according to the invention.
- 3,000 inhalation-flasks each containing 40 mg of 3-t-butyl-6-phenyl-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine (active compound) were prepared as follows:
Active compound 120 g Sorbitan trioleate 4 g propellent q.s. 60 l - Procedure
- The microcrystalline suspension prepared with these ingredients was introduced in the inhalation-flasks at a volume of 20 ml per flask with a filling machine. The flasks were furnished with an appropriate valve which released 0.2 ml of suspension for each activation (0.4 mg of active compound).
- 15,000 capsules each containing 20 mg of 3-t-butyl-6-phenyl-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine (active compound) were prepared from the following formulation:
Active compound 300 g Sodium carboxymethyl starch 330 g Talc 195 g Hydrogenated castor oil 165 g Corn starch 495 g - Procedure
- The above ingredients were sieved through a 60 mesh sieve, then mixed in a suitable mixer and filled into 15,000 gelatine capsules.
Claims (12)
1. A compound of formula (I)
wherein;
R1 represents a hydrogen atom or a —(CH2)m—Y group, wherein m is an integer from 0 to 4 and Y represents an alkyl, haloalkyl, alkoxy, alkoxycarbonyl, C3-C7 cycloalkyl, norbornyl or phenylalkenyl group, or an aromatic group which aromatic group Y may optionally be substituted by one or more halogen atoms;
R2 represents an aromatic group which aromatic group may optionally be substituted by one or more halogen atoms or alkyl, alkoxy, C3-C6 cycloalkoxy, methylenedioxy, nitro, dialkylamino or trifluoromethyl groups; and
R3 represents a hydrogen or halogen atom or an alkyl group,
and pharmaceutically acceptable salts thereof.
2. A compound according to claim 1 wherein the alkyl, haloalkyl and alkoxy groups have up to 6 carbon atoms, the alkoxycarbonyl groups have up to 7 carbon atoms and the phenylalkenyl groups have up to 12 carbon atoms.
3. A compound according to claim 1 or 2 wherein R1 represents —(CH2)m—Y wherein m is 0 or 1 and Y represents C1-6 alkyl or C3-7 cycloalkyl.
4. A compound according to any one of the preceding claims wherein R2 represents a phenyl group, naphthyl group or thienyl group which group R2 may optionally be substituted by one or more halogen atoms, methyl groups, methoxy groups, cyclopentoxy groups, nitro groups or dimethyl amino groups.
5. A compound according to claim 4 wherein R2 represents a phenyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 4-fluorophenyl or 3-nitrophenyl group.
6. A compound according to any one of the preceding claims wherein R3 represents a hydrogen atom, a C1-6 alkyl group or a chlorine atom at the 8- or 9-position of the 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine skeleton.
7. A compound according to claim 1 which is 6-(4-fluorophenyl)-3-isobutyl-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine, 3-cyclopropylmethyl-6-(3-nitrophenyl)-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine, 3-cyclopropyl-6-phenyl-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine and 3-cyclobutylmethyl-6-(3-nitrophenyl)-1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine.
8. A process for preparing a compound of formula (I)
wherein;
R1 represents a hydrogen atom or a —(CH2)m—Y group, wherein m is an integer from 0 to 4 and Y represents an alkyl, haloalkyl, alkoxy, alkoxycarbonyl, C3-C7 cycloalkyl, norbornyl or phenylalkenyl group, or an aromatic group which aromatic group Y may optionally be substituted by one or more halogen atoms;
R2 represents an aromatic group which aromatic group may optionally be substituted by one or more halogen atoms or alkyl, alkoxy, C3-C6 cycloalkoxy, methylenedioxy, nitro, dialkylamino or trifluoromethyl groups; and
R3 represents a hydrogen or halogen atom or an alkyl group,
which process comprises formation of the 1,2,4-triazine ring present in formula (I) by cyclisation of a hydrazide of formula (IV)
wherein R1, R2 and R3 are as defined above.
9. A composition comprising a compound according to any one of claims 1 to 7 or pharmaceutically acceptable salt thereof mixed with a pharmaceutically acceptable diluent or carrier.
10. A compound according to anv one of claims 1 to 7 or pharmaceutically acceptable salt thereof or a composition according to claim 9 for use in a method of treatment of the human or animal body.
11. Use of a compound according to any one of claims 1 to 7 or pharmaceutically acceptable salt thereof or a composition according to claim 9 for the manufacture of a medicament for the treatment of a condition whose known treatment is to inhibit phosphodiesterase 4 including allergic reaction and disease states, inflammation, ulcers and immunological disease.
12. A method of treating a condition whose known treatment is to inhibit phosphodiesterase 4 which comprises administering to a human or animal subject in need of such treatment an effective amount of compound according to any one of claims 1 to 7 or pharmaceutically acceptable salt thereof or a composition according to claim 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/038,777 US20020183326A1 (en) | 1997-07-29 | 2002-01-08 | 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009701670A ES2137113B1 (en) | 1997-07-29 | 1997-07-29 | NEW DERIVATIVES OF TRIAZOLO-PIRIDAZINAS HETEROCICLICOS. |
ES9701670 | 1997-07-29 | ||
EPPCT/EP98/04340 | 1998-07-13 | ||
PCT/EP1998/004340 WO1999006404A1 (en) | 1997-07-29 | 1998-07-13 | 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them |
US09/496,019 US6407108B1 (en) | 1997-07-29 | 2000-01-28 | 1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them |
US10/038,777 US20020183326A1 (en) | 1997-07-29 | 2002-01-08 | 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/496,019 Continuation US6407108B1 (en) | 1997-07-29 | 2000-01-28 | 1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020183326A1 true US20020183326A1 (en) | 2002-12-05 |
Family
ID=8300216
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/496,019 Expired - Fee Related US6407108B1 (en) | 1997-07-29 | 2000-01-28 | 1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them |
US10/038,777 Abandoned US20020183326A1 (en) | 1997-07-29 | 2002-01-08 | 1,2,4-triazolo[4,3-B]pyrido[3,2-D]pyridazine derivatives and pharmaceutical compositions containing them |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/496,019 Expired - Fee Related US6407108B1 (en) | 1997-07-29 | 2000-01-28 | 1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them |
Country Status (36)
Country | Link |
---|---|
US (2) | US6407108B1 (en) |
EP (1) | EP1001955B1 (en) |
JP (1) | JP4320118B2 (en) |
KR (1) | KR20010022353A (en) |
CN (1) | CN1135231C (en) |
AR (1) | AR015927A1 (en) |
AT (1) | ATE207069T1 (en) |
AU (1) | AU737709B2 (en) |
BG (1) | BG64448B1 (en) |
BR (1) | BR9810829B1 (en) |
CA (1) | CA2298935A1 (en) |
CO (1) | CO4970780A1 (en) |
CZ (1) | CZ290208B6 (en) |
DE (1) | DE69802100T2 (en) |
DK (1) | DK1001955T3 (en) |
EE (1) | EE04313B1 (en) |
EG (1) | EG24041A (en) |
ES (2) | ES2137113B1 (en) |
HK (1) | HK1024914A1 (en) |
HU (1) | HUP0004708A3 (en) |
ID (1) | ID24506A (en) |
IL (1) | IL134081A (en) |
MY (1) | MY118796A (en) |
NO (1) | NO315118B1 (en) |
NZ (1) | NZ502356A (en) |
PE (1) | PE111099A1 (en) |
PL (1) | PL191031B1 (en) |
PT (1) | PT1001955E (en) |
RU (1) | RU2202552C2 (en) |
SI (1) | SI1001955T1 (en) |
SK (1) | SK284046B6 (en) |
TR (1) | TR200000243T2 (en) |
TW (1) | TW542837B (en) |
UA (1) | UA60339C2 (en) |
WO (1) | WO1999006404A1 (en) |
ZA (1) | ZA986248B (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2792938B1 (en) | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NEWS 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES PHOSPHODIESTERASE IV INHIBITORS |
JP5038568B2 (en) | 1999-08-21 | 2012-10-03 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of synergists |
WO2002080974A1 (en) * | 2001-04-04 | 2002-10-17 | Sankyo Company, Limited | Novel medicinal use of cytokine production inhibitor |
PT1429807E (en) | 2001-09-19 | 2007-05-31 | Altana Pharma Ag | Combination of a nsaid and a pde-4 inhibitor |
FR2832711B1 (en) * | 2001-11-26 | 2004-01-30 | Warner Lambert Co | TRIAZOLO [4,3-A] PYRIDO [2,3-D] PYRIMIDIN-5-ONES DERIVATIVES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PREPARATION AND USE |
ATE524471T1 (en) * | 2002-11-06 | 2011-09-15 | Aska Pharm Co Ltd | PYRAZOLONAPHTHYRIDINE DERIVATIVE |
ES2211344B1 (en) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
RU2246496C1 (en) * | 2003-09-12 | 2005-02-20 | Тец Виктор Вениаминович | Substance with antiviral and antibacterial activity based on derivatives of 2,8-dithioxo-1h-pyrano[2,3-d; 6,5-d']dipyrimidine and their 10-aza-analogues |
ES2251866B1 (en) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
US8008317B2 (en) * | 2005-06-10 | 2011-08-30 | Merck Sharp & Dohme Corp. | Inhibitors of akt activtiy |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
AU2006289838B2 (en) * | 2005-09-15 | 2011-08-18 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound, and production process and use thereof |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2008021781A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
MX2009002496A (en) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinations containing a 4-acylaminopyridine derivative. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
AU2007323725B2 (en) | 2006-11-22 | 2014-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
EP2231669A1 (en) * | 2008-01-09 | 2010-09-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphodiesterase inhibitors |
HUE034716T2 (en) | 2008-05-21 | 2018-02-28 | Incyte Holdings Corp | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
AU2010338038B2 (en) | 2009-12-31 | 2015-07-09 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Tricyclic compounds for use as kinase inhibitors |
CN102812027B (en) | 2010-02-03 | 2015-01-07 | 因西特公司 | Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors |
EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3122670A1 (en) | 1981-06-06 | 1982-12-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | "NEW 1,4,9,10-TETRAHYDRO-PYRAZOLO (4,3-E) PYRIDO (3,2-B) (1,4) DIAZEPIN-10-ONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL ACTIVE SUBSTANCES " |
FI81350C (en) * | 1982-01-18 | 1990-10-10 | Lepetit Spa | ANALOGFOERFARANDE FOER FRAMSTAELLNING AV NYA, FARMAKOLOGISKT AKTIVA 6-SUBSTITUERADE S-TRIATSOLO / 3,4-A / PTHALAZINDERIVAT. |
AU7238191A (en) * | 1990-02-19 | 1991-09-03 | Chugai Seiyaku Kabushiki Kaisha | Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom |
TW365606B (en) * | 1991-10-09 | 1999-08-01 | Syntex Inc | Pyrido pyridazinone and pyridazinthione compounds |
GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
-
1997
- 1997-07-29 ES ES009701670A patent/ES2137113B1/en not_active Expired - Lifetime
-
1998
- 1998-07-13 WO PCT/EP1998/004340 patent/WO1999006404A1/en not_active Application Discontinuation
- 1998-07-13 PT PT78400158T patent/PT1001955E/en unknown
- 1998-07-13 CA CA002298935A patent/CA2298935A1/en not_active Abandoned
- 1998-07-13 PL PL338214A patent/PL191031B1/en not_active IP Right Cessation
- 1998-07-13 IL IL13408198A patent/IL134081A/en active IP Right Grant
- 1998-07-13 EP EP98940218A patent/EP1001955B1/en not_active Expired - Lifetime
- 1998-07-13 HU HU0004708A patent/HUP0004708A3/en unknown
- 1998-07-13 BR BRPI9810829-8A patent/BR9810829B1/en not_active IP Right Cessation
- 1998-07-13 SI SI9830042T patent/SI1001955T1/en unknown
- 1998-07-13 CZ CZ2000333A patent/CZ290208B6/en not_active IP Right Cessation
- 1998-07-13 TR TR2000/00243T patent/TR200000243T2/en unknown
- 1998-07-13 UA UA2000010486A patent/UA60339C2/en unknown
- 1998-07-13 AU AU88612/98A patent/AU737709B2/en not_active Ceased
- 1998-07-13 DE DE69802100T patent/DE69802100T2/en not_active Expired - Fee Related
- 1998-07-13 KR KR1020007000932A patent/KR20010022353A/en not_active Application Discontinuation
- 1998-07-13 DK DK98940218T patent/DK1001955T3/en active
- 1998-07-13 SK SK86-2000A patent/SK284046B6/en not_active IP Right Cessation
- 1998-07-13 AT AT98940218T patent/ATE207069T1/en not_active IP Right Cessation
- 1998-07-13 RU RU2000104863/04A patent/RU2202552C2/en not_active IP Right Cessation
- 1998-07-13 EE EEP200000052A patent/EE04313B1/en not_active IP Right Cessation
- 1998-07-13 ID IDW20000180A patent/ID24506A/en unknown
- 1998-07-13 JP JP2000505162A patent/JP4320118B2/en not_active Expired - Fee Related
- 1998-07-13 CN CNB988081210A patent/CN1135231C/en not_active Expired - Fee Related
- 1998-07-13 NZ NZ502356A patent/NZ502356A/en unknown
- 1998-07-13 ES ES98940218T patent/ES2162466T3/en not_active Expired - Lifetime
- 1998-07-14 ZA ZA986248A patent/ZA986248B/en unknown
- 1998-07-16 TW TW087111560A patent/TW542837B/en not_active IP Right Cessation
- 1998-07-27 MY MYPI98003421A patent/MY118796A/en unknown
- 1998-07-28 CO CO98042905A patent/CO4970780A1/en unknown
- 1998-07-29 EG EG88998A patent/EG24041A/en active
- 1998-07-29 AR ARP980103719A patent/AR015927A1/en active IP Right Grant
- 1998-07-30 PE PE1998000682A patent/PE111099A1/en not_active Application Discontinuation
-
2000
- 2000-01-26 NO NO20000394A patent/NO315118B1/en not_active IP Right Cessation
- 2000-01-27 BG BG104112A patent/BG64448B1/en unknown
- 2000-01-28 US US09/496,019 patent/US6407108B1/en not_active Expired - Fee Related
- 2000-06-15 HK HK00103595A patent/HK1024914A1/en not_active IP Right Cessation
-
2002
- 2002-01-08 US US10/038,777 patent/US20020183326A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6407108B1 (en) | 1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them | |
CA2339630C (en) | Carboline derivatives as cgmp phosphodiesterase inhibitors | |
AU702548B2 (en) | Chemical compounds | |
EP3040331B1 (en) | Tetrahydrocyclopentapyrrole derivative and preparation method therefor | |
CA2382919C (en) | Bicyclic imidazo-3-yl-amine derivatives | |
CZ211696A3 (en) | Tetracyclic derivatives, processes of their preparation, their use and pharmaceutical compositions containing thereof | |
CA2557785A1 (en) | Hiv integrase inhibitors | |
AU2002211827B2 (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
CA3128846A1 (en) | Difluoromethylene compound | |
JP2004501919A (en) | Chemical compound | |
TW200300344A (en) | Triazolo[4,3-a]pyrido[2,3-d]pyrimidin-5-one derivatives, compositions containing them, method of preparation and use | |
SK103093A3 (en) | New active compounds | |
JPS6267031A (en) | Alpha2-adrenalin receptor antagonist as gastro-intestinal peristalsis controlling substance | |
EP0548923A2 (en) | Antiallergic, antiinflammatory and anti-PAF pyridazine compounds | |
CZ265498A3 (en) | Triazole derivatives, process of their preparation and pharmaceutical composition containing thereof | |
MXPA00000910A (en) | 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them | |
KR101725292B1 (en) | Novel Pyrimidine-4-Carboxylic Acid Derivatives Having Anti-tumor Activity | |
JPH02290878A (en) | Benzothieno(furo)pyridine derivative | |
JP2000239277A (en) | Imidazoquinazoline derivative | |
JPS63277676A (en) | Ergoline derivative and acid addition salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |